MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/jaa.s156049

Медицинская библиотека · Journal of asthma and allergy · 2018

Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Ashkenazi Moshe, Sity Saray, Sarouk Ifat, Bar Aluma Bat El, Dagan Adi, Bezalel Yael, Bentur Lea, De Boeck Kris, Efrati Ori

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Allergic bronchopulmonary aspergillosis (ABPA) is a condition characterized by a Th2 response, serum eosinophilia, and increased total serum IgE to Aspergillus fumigatus. ABPA occurs in cystic fibrosis (CF) and asthma. Omalizumab is a humanized recombinant monoclonal antibody against IgE. Previous studies reported borderline results when treating ABPA with omalizumab.

METHODS

A retrospective study to investigate the efficacy of omalizumab in the treatment of ABPA in CF patients was conducted at 3 CF centers in Israel and Belgium. Data were obtained from the digital archive. We measured 4 outcome parameters: forced expiratory volume in 1 second, body mass index, pulmonary exacerbations, and steroid sparing.

RESULTS

The database was composed on the records of 9 patients. None of the outcome parameters showed any improvement. A favorable outcome was observed in patients with higher levels of posttreatment total IgE than those with lower levels. CF-related diabetes and male gender showed trends for poorer outcomes.

CONCLUSION

No benefits were detected on treating ABPA in CF with omlaizumb. Monitoring the total IgE was not helpful. A prospective randomized double-blind study is needed.

Для цитирования: Ashkenazi Moshe, Sity Saray, Sarouk Ifat, Bar Aluma Bat El, Dagan Adi, Bezalel Yael, Bentur Lea, De Boeck Kris, Efrati Ori. Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.. Journal of asthma and allergy. 2018. DOI: 10.2147/jaa.s156049.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.